MA49607A1 - Anticorps monoclonal pour il-5ra - Google Patents
Anticorps monoclonal pour il-5raInfo
- Publication number
- MA49607A1 MA49607A1 MA49607A MA49607A MA49607A1 MA 49607 A1 MA49607 A1 MA 49607A1 MA 49607 A MA49607 A MA 49607A MA 49607 A MA49607 A MA 49607A MA 49607 A1 MA49607 A1 MA 49607A1
- Authority
- MA
- Morocco
- Prior art keywords
- monoclonal antibody
- antibodies
- methods
- relates
- dnas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne le domaine de la biotechnologie et propose des anticorps qui se lient spécifiquement à il-5ra. L'invention concerne des adn qui codent pour lesdits anticorps, qui correspondent aux vecteurs d'expression, et des procédés de production ainsi que des méthodes de traitement utilisant ces anticorps.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017134413A RU2698048C2 (ru) | 2017-10-03 | 2017-10-03 | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
PCT/RU2018/050118 WO2019070164A1 (fr) | 2017-10-03 | 2018-10-02 | ANTICORPS MONOCLONAL POUR IL-5Rα |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49607A1 true MA49607A1 (fr) | 2021-03-31 |
Family
ID=65994565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49607A MA49607A1 (fr) | 2017-10-03 | 2018-10-02 | Anticorps monoclonal pour il-5ra |
Country Status (23)
Country | Link |
---|---|
US (1) | US20200291121A1 (fr) |
EP (1) | EP3693388A4 (fr) |
JP (1) | JP7275117B2 (fr) |
KR (1) | KR20200058537A (fr) |
CN (1) | CN111788223B (fr) |
AR (1) | AR113343A1 (fr) |
AU (1) | AU2018346116A1 (fr) |
BR (1) | BR112020006795A2 (fr) |
CA (1) | CA3078467A1 (fr) |
CL (1) | CL2020000920A1 (fr) |
CO (1) | CO2020004200A2 (fr) |
EA (1) | EA202090864A1 (fr) |
EC (1) | ECSP20024551A (fr) |
JO (1) | JOP20200106A1 (fr) |
MA (1) | MA49607A1 (fr) |
MX (1) | MX2020004026A (fr) |
PE (1) | PE20210466A1 (fr) |
PH (1) | PH12020550218A1 (fr) |
RU (1) | RU2698048C2 (fr) |
TW (1) | TWI758547B (fr) |
UY (1) | UY37914A (fr) |
WO (1) | WO2019070164A1 (fr) |
ZA (1) | ZA202002044B (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102697770B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인간 IL-5Rα에 결합하는 항체 및 이의 용도 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (fr) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Proteine cd2 soluble a deux domaines |
CA2046909A1 (fr) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination et methodes d'immunisation contre les maladies resultant de reactions pathogenes provoquees par des populations de lymphocytes t |
WO1991000360A1 (fr) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
IL95125A (en) | 1989-07-19 | 1995-07-31 | Vandenbark Arthur Allen | T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
KR0149181B1 (ko) | 1990-06-29 | 1998-08-17 | 데이비드 알, 맥지 | 형질전환된 미생물에 의한 멜라닌의 제조방법 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997010354A1 (fr) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
FR2783326B1 (fr) * | 1998-09-10 | 2000-12-01 | Immunotech Sa | Procede de detection ou de quantification des basophiles et des eosinophiles |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
RU2280255C2 (ru) * | 2000-09-14 | 2006-07-20 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Модуляция il-2- и il-15-опосредованных т-клеточных ответов |
SI1527100T1 (sl) * | 2002-03-29 | 2009-12-31 | Schering Corp | Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo |
JPWO2005035583A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Il−5受容体に特異的に結合する抗体組成物 |
US20050226867A1 (en) * | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
ES2558689T3 (es) * | 2007-05-14 | 2016-02-08 | Medimmune, Llc | Métodos para reducir los niveles de eosinófilos |
KR101398363B1 (ko) * | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
WO2015172800A1 (fr) | 2014-05-12 | 2015-11-19 | Numab Ag | Nouvelles molécules multispécifiques et nouvelles méthodes de traitement basées sur ces molécules multispécifiques |
MX368508B (es) * | 2013-08-12 | 2019-10-07 | Astrazeneca Ab | Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. |
EP3060579A1 (fr) * | 2013-10-25 | 2016-08-31 | Numab AG | Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies |
-
2017
- 2017-10-03 RU RU2017134413A patent/RU2698048C2/ru active
-
2018
- 2018-09-28 TW TW107134501A patent/TWI758547B/zh active
- 2018-10-02 MX MX2020004026A patent/MX2020004026A/es unknown
- 2018-10-02 US US16/753,488 patent/US20200291121A1/en active Pending
- 2018-10-02 MA MA49607A patent/MA49607A1/fr unknown
- 2018-10-02 KR KR1020207012627A patent/KR20200058537A/ko not_active Application Discontinuation
- 2018-10-02 EA EA202090864A patent/EA202090864A1/ru unknown
- 2018-10-02 CN CN201880078306.5A patent/CN111788223B/zh active Active
- 2018-10-02 CA CA3078467A patent/CA3078467A1/fr active Pending
- 2018-10-02 JO JOP/2020/0106A patent/JOP20200106A1/ar unknown
- 2018-10-02 BR BR112020006795-4A patent/BR112020006795A2/pt unknown
- 2018-10-02 AU AU2018346116A patent/AU2018346116A1/en active Pending
- 2018-10-02 EP EP18864122.9A patent/EP3693388A4/fr active Pending
- 2018-10-02 PE PE2020000514A patent/PE20210466A1/es unknown
- 2018-10-02 WO PCT/RU2018/050118 patent/WO2019070164A1/fr unknown
- 2018-10-02 JP JP2020519415A patent/JP7275117B2/ja active Active
- 2018-10-03 UY UY0001037914A patent/UY37914A/es unknown
- 2018-10-04 AR ARP180102863A patent/AR113343A1/es unknown
-
2020
- 2020-04-03 CL CL2020000920A patent/CL2020000920A1/es unknown
- 2020-04-03 CO CONC2020/0004200A patent/CO2020004200A2/es unknown
- 2020-04-03 PH PH12020550218A patent/PH12020550218A1/en unknown
- 2020-05-04 ZA ZA2020/02044A patent/ZA202002044B/en unknown
- 2020-05-06 EC ECSENADI202024551A patent/ECSP20024551A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019070164A1 (fr) | 2019-04-11 |
AU2018346116A1 (en) | 2020-05-14 |
JOP20200106A1 (ar) | 2020-05-06 |
CL2020000920A1 (es) | 2020-10-16 |
CN111788223B (zh) | 2024-08-30 |
PH12020550218A1 (en) | 2021-02-15 |
ECSP20024551A (es) | 2020-06-30 |
EP3693388A1 (fr) | 2020-08-12 |
AR113343A1 (es) | 2020-04-22 |
UY37914A (es) | 2019-04-30 |
CO2020004200A2 (es) | 2020-04-24 |
TWI758547B (zh) | 2022-03-21 |
US20200291121A1 (en) | 2020-09-17 |
TW201922789A (zh) | 2019-06-16 |
PE20210466A1 (es) | 2021-03-08 |
KR20200058537A (ko) | 2020-05-27 |
RU2698048C2 (ru) | 2019-08-21 |
BR112020006795A2 (pt) | 2020-10-06 |
CA3078467A1 (fr) | 2019-04-11 |
EA202090864A1 (ru) | 2020-06-29 |
JP2021501568A (ja) | 2021-01-21 |
CN111788223A (zh) | 2020-10-16 |
MX2020004026A (es) | 2020-08-13 |
RU2017134413A3 (fr) | 2019-04-03 |
RU2017134413A (ru) | 2019-04-03 |
ZA202002044B (en) | 2022-08-31 |
JP7275117B2 (ja) | 2023-05-17 |
EP3693388A4 (fr) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
MA49034B1 (fr) | Anticorps anti-lag3 | |
MA49599B1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
EA201992038A1 (ru) | Анти-псф-тау-антитела и способы их применения | |
PH12018502613A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
MA40476A (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
MA41596A (fr) | Anticorps anti-tau et leurs utilisations | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
MX2023011561A (es) | Anticuerpos anti-nectina-4 y usos de los mismos. | |
MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
MA43600B2 (fr) | Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire | |
MA53186B2 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
EA201891196A1 (ru) | Cgrp-антитела и их применение | |
EA202090929A1 (ru) | Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения | |
EA202092981A1 (ru) | Антитела к l1cam и их применение | |
EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
MA41930A1 (fr) | Composition pour traitement de la maladie du bayoud | |
MA41666B1 (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA39300A1 (fr) | Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations | |
MA41826B1 (fr) | Anticorps anti-icos | |
EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения |